News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oxford BioMedica PLC (OXB.L) to Present at Conference



8/29/2012 9:49:54 AM

OXFORD, UNITED KINGDOM--(Marketwire - August 29, 2012) -

Oxford BioMedica to Present at the 2012 Rodman & Renshaw Annual Global Investment Conference -- 14th Annual Healthcare Conference -- Oxford, UK - 29 August 2012: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that John Dawson, Chief Executive Officer of Oxford BioMedica, will present at the Rodman & Renshaw Annual Global Investment Conference to be held on September 9-11, 2012 at The Waldorf Astoria, NY (USA). The presentation is scheduled for Monday, 10 September 2012 at 16:30 Eastern Time. A copy of the slide presentation will be made available on the "Investors/Corporate presentations" section of the Company's website at www.oxfordbiomedica.co.uk. -Ends- For further information, please contact: Oxford BioMedica plc: Tel: +44 (0)1865 783 000 Lara Mott, Head of Corporate Communications Media Enquiries: Tel: +44 (0)20 7920 2360 Mary Clark/Sarah Macleod/Claire Dickinson M:Communications Notes to editors 1. Oxford BioMedica® Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk. This information is provided by RNS The company news service from the London Stock Exchange END

Contacts:
RNS
Customer
Services
0044-207797-4400
Email Contact
http://www.rns.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES